Dow Jones 30 Stocks SEC Filings — March 11, 2026

11-03-2026

GameSquare Holdings, Inc. received a second Nasdaq notice on March 10, 2026, granting an additional 180 calendar days until September 7, 2026, to regain compliance with the $1.00 minimum bid price rule after failing the initial 180-day period ending March 9, 2026. The company meets other Nasdaq Capital Market listing requirements except bid price and plans a potential reverse stock split. However, failure to achieve $1.00 closing bid price for 10-20 consecutive business days risks delisting, with no assurance of compliance.

• ·Initial deficiency notice received September 10, 2025, for 30 consecutive business days below $1.00 bid price.
• ·Reverse stock split, if implemented, must be completed no later than 10 business days prior to September 7, 2026.
• ·Company eligible for extension based on meeting market value of publicly held shares and other initial listing requirements.

11-03-2026

Advasa Holdings, Inc., a Delaware-incorporated emerging growth company and holding company with operations in the US and Japan (SIC 7372), filed Pre-Effective Amendment No. 3 to its Form S-1 (Reg. No. 333-292013) on March 10, 2026, registering 485,469,380 shares of common stock (par value $0.00001) for resale by existing Registered Stockholders via a direct listing on Nasdaq Global Market under symbol 'ADBT', with no proceeds to the company and costs borne by it for compliance. The direct listing lacks traditional underwriting, potentially leading to higher volatility and no established public market, while a 10-for-1 forward stock split was effective December 4, 2025; trading is expected on or about [_____], 2026, subject to Nasdaq approval, which if denied would terminate the process. Investing involves a high degree of risk as highlighted in the prospectus.

• ·Registrant classified as non-accelerated filer, smaller reporting company, and emerging growth company.
• ·Principal executive offices: 1-2-7 Moto-Akasake, Minato-ku, Tokyo, 107-0051 Japan.
• ·Agent for service: Corporate Creations Network Inc., 1521 Concord Pike, Suite 201, Wilmington, Delaware 19803.
• ·Shares eligible under Rule 415 for delayed or continuous offering.

11-03-2026

Cantor Equity Partners V, Inc. appointed Charlotte Blechman as a Class I director, Audit Committee member, and Compensation Committee member, effective March 10, 2026. Ms. Blechman brings extensive experience in marketing, branding, and public relations, including roles as Senior Managing Director at ACTUM since November 2025 and prior positions at Tom Ford Retail LLC and Barneys New York, as well as directorships at multiple SPACs. In connection with her appointment, the Board approved $50,000 annual compensation, paid quarterly.

• ·Ms. Blechman served as Chief Marketing Officer of Tom Ford Retail LLC from January 2017 to June 2023.
• ·No family relationships between Ms. Blechman and any director or executive officer.
• ·Company is an emerging growth company; Class A ordinary shares trade as CEPV on Nasdaq.

11-03-2026

Aptevo Therapeutics Inc. announced new interim clinical data on March 10, 2026, for mipletamig in combination with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia (AML) patients via a press release filed as Exhibit 99.1. No financial metrics or period-over-period comparisons were disclosed in the 8-K. The announcement highlights ongoing clinical development without specific quantitative outcomes provided.

• ·Filing date: March 11, 2026
• ·Date of earliest event reported: March 10, 2026
• ·Trial focus: newly diagnosed acute myeloid leukemia (AML) patients

11-03-2026

On March 6, 2026, CERO Therapeutics Holdings, Inc. issued and sold a convertible promissory note to Keystone Capital Partners, LLC for a purchase price of $750,000, with a principal face value of $937,500 and capacity to borrow up to an aggregate of $1M. The note carries 10% annual interest, matures on August 6, 2027, and is convertible into common stock at the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices over the prior 20 trading days, subject to a 4.99% beneficial ownership limit. The transaction relies on exemptions under Section 4(a)(2) and Rule 506(b) of the Securities Act, with the company required to file a resale registration statement.

• ·Note form incorporated by reference from February 13, 2026 Form 8-K (Exhibit 4.1)
• ·Issued in reliance on Section 4(a)(2) of the Securities Act and Rule 506(b)
• ·Company to file Form S-1 or S-3 registration statement for resale of conversion shares

11-03-2026

AeroVironment's Q3 revenue surged 143% YoY to $408M, propelled by acquisitions introducing Space and Directed Energy ($53M) and Cyber and Mission Services ($76M) segments, with Precision Strike up 87% to $158M; nine-month revenue rose 145% to $1.3B. However, a $151M goodwill impairment, elevated SG&A (up 127% to $99M), and higher debt interest contributed to a Q3 net loss of $157M (vs $1.8M loss) and nine-month net loss of $241M (vs $27M profit), with Uncrewed Aircraft Systems revenue nearly flat nine-month YoY at $243M. Total assets expanded to $5.45B from $1.12B as of April 30, 2025, reflecting acquisitions funded by $2.6B stock issuance and $728M long-term debt.

• ·Cash used in operating activities nine months: $174M (vs $1M prior)
• ·Business acquisitions net of cash: $845M
• ·Proceeds from shares issued: $969M
• ·Proceeds from convertible debt: $727M
• ·Allowance for credit losses: $2.2M (up from $0.2M)

11-03-2026

Blue Water Acquisition Corp. IV (BWIV), a SPAC, filed an S-1/A registration statement on March 11, 2026, for its initial public offering of units at an offering price of $10.00 per unit. The filing includes extensive pro forma tables detailing net tangible book value per share across scenarios with and without overallotment option exercise and public shareholder redemptions at 0%, 25%, 50%, 75%, or 100% of maximum as of December 31, 2025. Founder shares were issued on August 1, 2025, and private placement units are referenced for the sponsor.

• ·Pro forma net tangible book value calculations exclude offering costs accrued or paid in advance, deferred underwriting commissions, overallotment liability, and redemptions
• ·Scenarios assume ordinary shares outstanding prior to offering and potential founder share forfeitures if overallotment not exercised

11-03-2026

Johnson & Johnson (JNJ) filed Definitive Additional Proxy Materials (DEFA14A) on March 11, 2026, as a supplement to its proxy statement under Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is marked as Definitive Additional Materials. No specific proposals, financial data, or voting matters are detailed in the provided content.

• ·Filing categorized as Soliciting Material under § 240.14a-12

11-03-2026

Minerva Neurosciences reported FY 2025 financial results with $80M gross proceeds from an October 2025 private placement, boosting cash to $82.4M from $21.5M at year-end 2024, and plans to initiate a confirmatory Phase 3 trial for roluperidone in Q2 2026 with topline data in 2H 2027. However, GAAP net loss widened dramatically to $293.4M for FY 2025 from $1.4M net income in 2024, driven by $321.5M non-cash loss on convertible preferred stock and warrant issuance, while R&D expenses declined 51% YoY to $5.8M but G&A rose 12% in Q4 to $2.8M. Non-GAAP adjusted net loss improved to $16.0M from $19.3M for the full year.

• ·Warrant liability fair value at Dec 31, 2025: $171.5M, with $45.4M non-cash gain on change in fair value for FY 2025.
• ·Non-GAAP total liabilities: $2.3M at Dec 31, 2025 vs $2.8M at Dec 31, 2024 (slight decline).
• ·Q4 GAAP net loss per share: $25.51 vs $0.56 prior year; FY GAAP net loss per share: $34.67 vs $0.19 net income per share prior year.

11-03-2026

Serve Robotics reported strong revenue growth with Q4 2025 at $0.9M (up ~400% YoY from $0.2M) and full year 2025 at $2.7M (exceeding $2.5M guidance and up 46% YoY from $1.8M), scaling fleet to 2,000 robots across 20 cities in 6 metro areas while achieving 99.8% delivery completion. However, net losses widened dramatically to $101M for full year 2025 from $39M in 2024, with Q4 loss at $34M amid surging operating expenses ($97M vs $38M prior year) and gross losses. The company raised 2026 revenue guidance to $26M and maintained $260M liquidity, bolstered by four strategic acquisitions diversifying into healthcare and AI.

• ·Daily Active Robots increased to 547 in Q4 2025 from 312 in Q3 2025 and 257 in Q4 2024.
• ·Recurring revenues grew over 4x from ~$0.2M in Q1 2025 to over $0.8M in Q4 2025.
• ·Software services revenue: $1.0M full year 2025 vs $1.2M in 2024 (slight decline).
• ·Net cash used in operating activities: $80M for both full year 2025 and 2024.

11-03-2026

Vistagen Therapeutics, Inc. implemented a Board-approved 20% workforce reduction on March 5, 2026, aimed at disciplined cash management while prioritizing the PALISADE Program clinical studies for fasedienol in social anxiety disorder. The company anticipates immaterial costs from severance and benefits, with a cash runway extending into 2027, though additional unforeseen costs may arise. Topline results from the PALISADE-4 Phase 3 trial are expected in the first half of 2026.

• ·Affected employees may receive cash severance and temporary healthcare coverage upon signing a separation agreement with general release of claims.
• ·Filing date: March 11, 2026.
• ·Costs incurred expected to be immaterial, but additional costs may occur due to associated events.

11-03-2026

Bread Financial Holdings, Inc. filed an 8-K on March 11, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, announcing a press release with a performance update as of and for the period ended February 28, 2026 (Exhibit 99.1). The press release is furnished but not deemed 'filed' under Section 18 of the Exchange Act. No specific financial metrics or period-over-period comparisons were detailed in the filing body.

• ·Securities registered: Common Stock (BFH, NYSE); Depository Shares for 8.625% Non-Cumulative Perpetual Preferred Stock, Series A (BFH PrA, NYSE).

11-03-2026

Sonida Senior Living, Inc. completed its $1.8B strategic merger with CNL Healthcare Properties, Inc., acquiring 100% of CHP for $7.22 per share ($4.58 stock + $2.32 cash), creating a $3.3B pure-play senior housing owner-operator with 153 owned communities (~14,700 units), making it the eighth largest U.S. senior living owner. The deal delivers estimated 62% Normalized FFO per share accretion on a run-rate basis, with Sonida's existing shareholders owning 50% of the combined entity, and strengthens the balance sheet via $930M permanent debt financing (expandable to $1.25B). No quantitative declines reported, though forward-looking risks include integration challenges and debt refinancing.

• ·Merger agreement dated November 4, 2025; Sonida stockholder meeting February 26, 2026 (91% quorum, 18,277,189 shares present); exchange ratio 0.1318x based on $4.58 stock value and VWAP with 15%-30% collar ($22.73-$34.76 reference).
• ·CHP external advisor resources available for 90 days post-closing; some employees joining permanently.
• ·Sam Levinson to join Board effective May 1, 2026.
• ·Portfolio spans South, Southeast, Midwest, Mountain West, Pacific Northwest, Mid-Atlantic; 54 communities managed by third-parties, 15 leased, 4 JV consolidated, 4 JV unconsolidated.

11-03-2026

BKV Corporation filed an 8-K on March 11, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, furnishing two press releases: Exhibit 99.1 dated March 10, 2026, announcing a securities offering, and Exhibit 99.2 dated March 11, 2026, announcing the pricing of the offering. The disclosures include standard disclaimers that the information is not an offer to sell securities and is not deemed 'filed' under the Exchange Act.

• ·Filing Type: 8-K, Items: 7.01, 9.01
• ·Subcategory: Regulation FD Disclosure
• ·Exhibits include 104 Cover Page Interactive Data File

11-03-2026

Valmont Industries, Inc. issued definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting scheduled for April 27, 2026. Key proposals include election of four director nominees (Mogens C. Bay, Ritu Favre, Richard A. Lanoha, Paul T. Maass), approval of the Valmont 2026 Employee Stock Purchase Plan, advisory vote on executive compensation, and ratification of independent auditors for fiscal 2026, with the board recommending 'For' all items. No financial metrics or performance data are disclosed in this notice.

• ·Voting deadline: April 26, 2026 11:59 PM ET (April 22, 2026 11:59 PM ET for shares held in a Plan)
• ·Proxy materials request deadline: April 13, 2026
• ·Meeting location: 15000 Valmont Plaza, Omaha, NE 68154
• ·Meeting time: 10:00 AM on April 27, 2026

11-03-2026

Mainz Biomed N.V. (NASDAQ: MYNZ) appointed Robert P. Liscouski as Chairman of its Board of Directors, effective pending approval at an extraordinary general meeting in April 2026, while planning to change its name to Quantum Cyber and Nasdaq ticker to QUCY starting March 12, 2026. The company continues progress on its pancreatic cancer screening business in the U.S., evaluating sale of colorectal cancer screening assets, and winding down its German subsidiary. Mr. Liscouski brings over 35 years of experience in cybersecurity, AI, quantum computing, and government infrastructure protection.

• ·Name and ticker changes (to Quantum Cyber / QUCY) effective for business and trading on March 12, 2026; permanent election and name change at EGM in April 2026
• ·Prior SEC filings referenced: Form 20-F filed March 31, 2025; Form 6-K filed September 26, 2025

11-03-2026

Marvell Technology, Inc. reported FY2026 net revenue of $8,194.6 million, up 42.1% YoY from $5,767.3 million, with gross profit surging 75.5% to $4,180.7 million and margin expanding to 51.0% from 41.3%, driving a swing to operating income of 16.1% and net income of 32.6% from prior losses. However, cost of goods sold rose 18.6% to $4,013.9 million, R&D expenses increased 6.4% to $2,075.2 million, while SG&A dipped slightly by 3.9% and restructuring charges fell sharply to 0.2% of revenue from 6.1%. Total facilities include 983,000 sq ft owned and 1,515,000 sq ft leased, primarily outside the US.

• ·Stock-based compensation totaled $590.8M in FY2026, slightly down from $597.4M in FY2025, with breakdowns: COGS $49.2M (up from $47.3M), R&D $409.0M (up from $395.6M), SG&A $132.6M (down from $154.5M).

11-03-2026

Strategic Education, Inc. (STRA) filed Definitive Additional Proxy Materials (DEFA14A) on March 11, 2026, for its virtual Annual Meeting of Stockholders on April 22, 2026, at 8:00 A.M. ET. Key proposals include the election of 12 directors, ratification of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026, and advisory approval of named executive officer compensation. The Board recommends voting 'FOR' all proposals, with proxy materials available online and voting options via internet.

• ·Paper/email copy requests due by April 14, 2026
• ·Virtual meeting registration deadline: April 18, 2026 at 11:59 P.M. ET
• ·Voting via www.AALvote.com/STRA using 11-digit Virtual Control Number

11-03-2026

Vista Gold Corp reported a net loss of $7.5M for 2025, compared to a $11.2M net income in 2024, driven by higher exploration and holding costs of $5.6M (up 62% YoY) and the absence of one-time gains like the $16.9M royalty grant. Cash and equivalents declined 20% to $13.6M from $17.0M, with total assets down 14% to $16.3M and shareholders' equity falling 16% to $15.1M; however, management believes working capital plus $41.9M net proceeds from an offering will fund operations and Mt Todd programs. Planned Mt Todd capital expenditures total $425M initial and $442M sustaining, with no revenue generated in either year.

• ·Corporate administration expenses remained flat at approximately $3.6M YoY.
• ·Proceeds from equity financing net: $4.3M in 2025 vs $1.1M in 2024.
• ·Capitalized mineral property development costs: $0.15M in 2025 vs $1.9M in 2024 (decline).

11-03-2026

Netskope reported strong Q4 FY2026 results with ARR up 31% YoY to $811M and revenue up 32% YoY to $196.3M, alongside FY2026 revenue growth of 32% to $709M and first full year of positive free cash flow at $12.4M. Gross margins improved (GAAP 73% vs 67% in Q4, non-GAAP 76% vs 72%), and non-GAAP operating margins narrowed to -10% from -15% in Q4. However, GAAP operating losses widened significantly to -58% margin in Q4 (vs -28% prior) and -92% for FY (vs -48%), with Q4 free cash flow remaining flat at $4M (2% margin vs 3%).

• ·Lock-up period ends March 13, 2026, making ~390M shares eligible for sale.
• ·Q1 FY2027 guidance: revenue $197M-$199M; FY2027 revenue $870M-$876M, non-GAAP gross margin ~77%, FCF margin 2-4%.
• ·Conference call at 2:00 p.m. PT on March 11, 2026.

11-03-2026

Unity Bancorp, Inc. filed a supplement to its definitive proxy statement dated March 6, 2026, solely to correct a typographical error on page 4 regarding diluted EPS disclosure, amending it from three months ending December 31, 2025, to full-year diluted EPS. No other changes were made to the original proxy statement, which remains in effect for the Annual Meeting of Stockholders on April 23, 2026. This filing does not introduce new financial data or performance metrics.

• ·Original proxy statement filed with SEC on March 6, 2026.
• ·Supplement dated March 10, 2026; filing date March 11, 2026.
• ·Address: 64 Old Highway 22, Clinton, NJ 08809

11-03-2026

PNC Financial Services Group, Inc. issued definitive additional proxy materials for its 2026 Annual Meeting on April 22, 2026, at 11:00 a.m. ET virtually. Shareholders are asked to vote on the election of 13 director nominees, ratification of PricewaterhouseCoopers LLP as independent auditor for 2026, an advisory vote on named executive officer compensation, and approval of the 2026 Omnibus Equity Incentive Plan, with the Board recommending 'FOR' all items. No financial performance data or comparisons are provided in the notice.

• ·Vote deadline: 11:59 p.m. ET on April 21, 2026
• ·Proxy materials request deadline: April 8, 2026
• ·Virtual meeting location: www.virtualshareholdermeeting.com/PNC2026

11-03-2026

Joby Aviation's affiliate, 1669 Capstone Way, LLC, entered into a $30.75M loan agreement dated March 6, 2026, with B UL LLC, secured by the property at 1669 Capstone Way, Vandalia, Ohio 45377. The loan features an interest rate of 6.784% and an alteration threshold of $1M. No performance declines or flat metrics are reported in this financing agreement.

• ·Loan application dated January 6, 2026
• ·Property address: 1669 Capstone Way, Vandalia, Ohio 45377
• ·Borrower address: 333 Encinal Street, Santa Cruz, California 95060

11-03-2026

Travelzoo's DEF 14A proxy statement for the virtual Annual Meeting of Stockholders on April 20, 2026, solicits votes to elect five board directors (each for a one-year term until 2027), approve option grants to the Global Chief Executive Officer (Proposal 2), General Manager U.S. (Proposal 3), and Head of Engineering (Proposal 4), and provide an advisory vote on executive compensation (Proposal 5). As of the March 5, 2026 record date, 10,932,337 shares of Common Stock were outstanding, with Azzurro Capital Inc. (beneficially owned by founder Ralph Bartel) holding 3,662,696 shares or 33.5%. The Board recommends voting FOR all proposals; no financial performance metrics or period comparisons are provided.

• ·Record date: 5:00 p.m. ET on March 5, 2026
• ·Meeting: April 20, 2026 at 10:00 a.m. ET, virtual only at www.virtualshareholdermeeting.com/TZOO2026
• ·Quorum requires majority of outstanding shares present in person or by proxy
• ·Proposals 1-5 are non-routine; broker non-votes have no effect on outcomes

11-03-2026

11-03-2026

UWM Holdings Corporation is pursuing the acquisition of Two Harbors Investment Corp (TWO), offering enhanced scale with a pro forma market cap of ~$7.6B (7x TWO standalone), $2.2B float, and complementary origination-servicing capabilities. UWM reported Q4 2025 origination volume of $49.6B, its highest in 4 years with Gain on Sale margins up 17bps YoY, and projects Q1 2026 revenue of $800M-$900M and FY2026 revenue of $3.5B-$4.5B. The deal promises ~$150M cost synergies and TWO's board endorsement, though subject to risks like integration challenges and market conditions.

• ·UWM has issued quarterly dividend of $0.10 per share every quarter since 2021.
• ·TWO unaffected stock price of $9.91 as of 12/16/2025.
• ·Analyst consensus price target $6.00 implying 49% upside from current $4.04 stock price (3/10/2026); recent high $6.10 (1/16/2026), 52-week high $7.14.

11-03-2026

KLX Energy Services Holdings reported full year 2025 revenue of $637M but a net loss of $77M (-12% margin), with Adjusted EBITDA of $76M (12% margin). Q4 2025 revenue declined 5.9% QoQ to $156.8M and was roughly flat YoY at $165.5M, though Adjusted EBITDA rose 7% QoQ to $22.5M (14.3% margin, yearly high) driven by Northeast/Mid-Con strength (+0.5% QoQ revenue). However, Rocky Mountains and Southwest segments saw revenue drops of 8.9% and 10.1% QoQ, respectively, amid seasonality.

• ·Issued warrants for up to 803,712 shares at $0.01 exercise price in connection with indenture amendment on March 6, 2026.
• ·Total debt $258.3M at 12.3% interest rate as of Dec 31, 2025.
• ·Conference call scheduled for March 12, 2026 at 10:00 a.m. ET.

11-03-2026

Levi Strauss & Co. reported FY25 net revenues of $6.3B, up 7% organically, achieving a record gross margin of 61.7% and adjusted EBIT margin of 11.4% (up 70 basis points YoY), with adjusted diluted EPS of $1.34 and $363M returned to shareholders (up 26% from 2024). The proxy statement seeks shareholder approval for election of Class I directors, advisory vote on executive compensation, ratification of auditors, and opposes a shareholder proposal on sustainability ROI reporting. Board Chair Robert A. Eckert will step down after the April 22, 2026 annual meeting, with Troy Alstead succeeding him.

• ·Annual shareholder meeting scheduled for April 22, 2026 at 10:30 a.m. PT via virtual webcast.
• ·Shareholder record date: February 27, 2026.
• ·Fiscal year ended November 30, 2025.
• ·Board added four new independent directors over past three years: David Marberger, Artemis Patrick, Daniel Geballe, Jeffrey J. Jones II.

11-03-2026

Consolidated Edison Inc., through its subsidiaries Consolidated Edison Company of New York, Inc., Consolidated Edison, Inc., and Orange and Rockland Utilities, Inc., entered into a $3.5B revolving credit agreement on March 11, 2026, with Bank of America, N.A. as administrative agent, JPMorgan Chase Bank, N.A. and Mizuho Bank, Ltd. as syndication agents, and other banks as documentation agents and joint lead arrangers. The facility provides commitments for borrowings and letters of credit, with standard covenants including a debt to total capital ratio. No prior period comparisons or performance metrics are included.

• ·Deal CUSIP: 20911FAY8
• ·Revolving Credit CUSIP: 20911FAZ5
• ·Filing Items: 1.01, 1.02, 2.03, 9.01

11-03-2026

Comtech Telecommunications Corp. held its Fiscal 2025 Annual Meeting of Stockholders on March 9, 2026, electing all seven director nominees to the Board, though Mark R. Quinlan and Lawrence J. Waldman each received approximately 1.5M votes against amid total votes cast of around 38M. Stockholders also approved the advisory vote on named executive officer compensation (32.0M for vs. 5.6M against), ratified Deloitte & Touche LLP as the independent auditor for fiscal year ending July 31, 2026 (44.2M for), and approved an amendment to the 2023 Equity and Incentive Plan to increase available shares (37.1M for). All proposals passed consistent with Board recommendations, with broker non-votes around 6.1M.

• ·Proposal No. 2 votes: For 32,033,498; Against 5,598,343; Abstain 769,161
• ·Proposal No. 4 votes: For 37,122,608; Against 1,165,014; Abstain 113,382; Broker Non-Votes 6,134,311
• ·Kenneth H. Traub director votes: For 38,123,051; Against 259,978; Abstain 17,979

11-03-2026

Guardian Pharmacy Services, Inc. reported revenue of $1.45B for the year ended December 31, 2025, up 17.9% YoY from $1.23B in 2024, driven by gross profit growth to $293M. SG&A expenses fell 28.4% to $220M (15.2% of revenue vs. 25.0% prior year), swinging operating income to $73M from a $63M loss and net income attributable to $49M from a $110M loss; however, cost of goods sold as a percentage of revenue slightly improved to 79.8% from 80.1%. Adjusted EBITDA increased to $115M from $91M.

• ·Executive officers each have more than 30 years of experience in the pharmacy industry.
• ·Team began working together in 1993 on a previous pharmacy venture acquired by Bindley Western in 1999.
• ·Net income attributable to Guardian Pharmacy, LLC prior to Corporate Reorganization: $23M in 2024.
• ·Net income (loss) attributable to non-controlling interests: $16M in 2024 and -$0.3M in 2025.

11-03-2026

Life Time Group Holdings, Inc. filed definitive additional proxy materials (DEFA14A) on March 11, 2026, for its 2026 Annual Meeting on April 22, 2026, at 9:30 a.m. Central Time, held virtually. Shareholders will vote on electing five Class II directors (Joel Alsfine, Jonathan Coslet, J. Kristofer Galashan, Stuart Lasher, Jennifer Pomerantz), a non-binding advisory approval of named executive officer compensation, and ratification of Deloitte & Touche LLP as independent registered public accounting firm. Proxy materials are available online at www.ProxyVote.com, with voting due by April 21, 2026, 11:59 PM ET.

• ·Annual Meeting held virtually at www.virtualshareholdermeeting.com/LTH2026
• ·Proxy materials request deadline: April 8, 2026
• ·Company address: 2902 Corporate Place, Chanhassen, MN 55317
• ·Contact for materials: 1-800-579-1639 or sendmaterial@proxyvote.com

11-03-2026

Interactive Brokers Group, Inc. (IBKR) filed its DEF 14A proxy statement for the 2026 Annual Meeting on April 23, 2026, proposing the election of ten directors, ratification of Deloitte as independent auditor for fiscal year ending December 31, 2026, an advisory vote on executive compensation, and an amendment to extend the 2007 Stock Incentive Plan through April 27, 2037. The record date is February 24, 2026, and the meeting will be held virtually. All share and award information is presented on a post 4-for-1 stock split basis, with the split having a record date of June 16, 2025.

• ·Annual Meeting time: 9:30 a.m. Eastern Time, virtual at www.virtualshareholdermeeting.com/IBKR2026
• ·Stock split announced April 15, 2025; Board approval April 14, 2025; majority stockholder approval April 22, 2025
• ·2025 Annual Report available with proxy materials

11-03-2026

Biglari Holdings Inc. filed its definitive proxy statement for the annual shareholder meeting on April 8, 2026, at the Majestic Theatre in San Antonio, Texas, to elect five directors (Sardar Biglari, Philip L. Cooley, Ruth J. Person, Kenneth R. Cooper, and John G. Cardwell, with three independent) and ratify Deloitte & Touche LLP as the independent auditor for 2026. The record date is February 26, 2026, with 211,176.1 shares of Class A common stock outstanding entitled to vote. The Board held five meetings in 2025 with full attendance, two non-management director meetings, and the company notes it is a controlled company exempt from certain NYSE governance requirements.

• ·Board unanimously recommends voting FOR all five director nominees.
• ·Three nominees (Kenneth R. Cooper, Ruth J. Person, John G. Cardwell) are independent per NYSE standards.
• ·John G. Cardwell and Ruth J. Person qualify as audit committee financial experts.
• ·Company is a 'controlled company' under NYSE rules, exempt from certain director independence and committee requirements.
• ·No governance and nominating committee; no formal diversity policy for director nominees.
• ·Shareholders must register at proxyvote.com/register for admission tickets to the meeting; up to two guests allowed per shareholder.

11-03-2026

11-03-2026

Innovex International, Inc. (INVX), an oil and gas field machinery and equipment company (SIC 3533), filed an 8-K on March 11, 2026, disclosing other events under Item 8.01 and attaching exhibits under Item 9.01, with a filing size of 166 KB. The company, formerly Dril-Quip Inc., is headquartered in Humble, TX, with fiscal year end December 31. No specific financial metrics, period-over-period comparisons, or event details are provided in the filing index.

• ·CIK: 0001042893
• ·Business Address: 19120 KENSWICK DRIVE, HUMBLE TX 77338
• ·Phone: (346) 398-0000
• ·State of Incorporation: DE
• ·Formerly Dril-Quip Inc. (filings through 2024-09-05)

11-03-2026

Viant Technology Inc. reported revenue of $344.2M for the year ended December 31, 2025, up 19% YoY from $289.2M in 2024. Operating income improved significantly to $12.1M (4% of revenue) from $3.5M (1% of revenue), and net income attributable to the company rose to $8.4M from $2.4M. However, income before taxes declined 20% to $10.1M from $12.7M due to other expense of $1.9M versus income of $9.2M in 2024, while platform operations and sales & marketing expenses remained flat as a percentage of revenue at 54% and 19%, respectively.

• ·Stock-based compensation increased to $24.8M in 2025 from $21.0M in 2024.
• ·Total depreciation rose to $18.0M in 2025 from $16.3M in 2024.
• ·Total amortization increased to $0.7M in 2025 from $0.2M in 2024.
• ·Net income attributable to noncontrolling interests was $15.7M in 2025, up from $10.1M in 2024.
• ·Traffic acquisition costs grew 21% YoY to $135.5M in 2025.

11-03-2026

Evofem Biosciences, Inc.'s 10-K filing raises substantial doubt about its ability to continue as a going concern, citing material weaknesses in internal controls as of December 31, 2025 and 2024, over 90 days past due on significant vendor obligations, notices of default from Future Pak, LLC, and ongoing significant losses with negative cash flows. The company faces challenges in raising additional capital, remediating controls, commercializing PHEXX and SOLOSEC, and complying with debt arrangements, with no indications of near-term profitability. Risks include potential asset seizures, regulatory enforcement, and failure to meet Nasdaq or other listing standards.

• ·Over 90 days past due on significant vendor obligations.
• ·Material weaknesses in internal controls identified as of December 31, 2025 and December 31, 2024.
• ·FDA approval for PHEXX (as Femidence in Nigeria) for pregnancy prevention and SOLOSEC for BV and trichomoniasis treatment.

11-03-2026

At TE Connectivity plc's Annual General Meeting on March 11, 2026, all 13 director nominees were elected with overwhelming support (91.86% to 99.68% in favor), though Abhijit Y. Talwalkar (91.86% for, 8.14% against) and Heath A. Mitts (93.87% for, 6.13% against) faced the highest opposition. Shareholders ratified Deloitte auditors (97.84% for), approved advisory vote on executive compensation (92.08% for, 7.92% against), and authorized share repurchases (99.82% for) and treasury share re-allotment (99.61% for), with 90.59% quorum present. All proposals passed.

• ·Record date for AGM: January 8, 2026
• ·Ordinary shares par value: $0.01

11-03-2026

EDUCATIONAL DEVELOPMENT CORP filed an 8-K on March 11, 2026, disclosing under Item 1.01 entry into a material definitive agreement and under Item 9.01 financial statements and exhibits. No details on the agreement terms, parties involved, transaction value, strategic rationale, or financial impacts are provided in the filing summary. Specific quantitative metrics, period-over-period comparisons, or guidance changes are NOT_DISCLOSED.

11-03-2026

Tivic Health Systems, Inc. filed an 8-K on March 11, 2026, under Item 5.07 reporting submission of matters to a vote of security holders and under Item 8.01 disclosing other events. No specific voting outcomes, proposals, or details on the other events are provided in the filing summary. This multi-item filing provides informational disclosure without quantified financial metrics or directional impacts.

11-03-2026

BGSF reported Q4 2025 revenues of $22.0M, down 9.4% YoY from $24.3M and 18.1% QoQ from $26.9M, with gross profit declining to $7.7M (35.0% margin vs 35.9% prior), though net loss improved to $1.3M from $2.9M YoY due to cost cuts; FY 2025 revenues fell 10.6% to $93.3M from $104.4M. The company is now debt-free with $19.0M cash after selling its Professional division, paying a $2.00-per-share special dividend, and authorizing a $5M share repurchase. Strategic moves include rebranding to BG Staffing post-TSA with INSPYR Solutions in April 2026 and a PropTech partnership with Yardi.

• ·Company became debt-free post-sale of Professional division.
• ·Q4 Adjusted EBITDA loss of $0.9M improved from $1.6M YoY loss.
• ·Total assets $57.8M as of Dec 28, 2025, down from $150.1M prior year.
• ·Cash dividends declared $2.00 per common share in FY 2025.
• ·Conference call scheduled for March 12, 2026 at 9:00 a.m. ET.

11-03-2026